Infection with the Gram-negative, microaerophilic pathogen Helicobacter pylori results in gastric cancer in a subset of infected individuals. As such, H. pylori is the only WHO classified bacterial class I carcinogen. Numerous studies have identified mechanisms by which H. pylori alters host cell signaling pathways to cause disease. The purpose of this review is to highlight recent studies that explore mechanisms associated with induction of gastric cancer.
INTRODUCTION
Given its association with gastric cancer, the WHO classified Helicobacter pylori as a class I carcinogen in 1994; to date, H. pylori remains the only bacterium with this distinction [1, 2] . This Gram-negative, microaerophilic bacterium persistently colonizes the gastric mucosa of the majority of the population. Although, infections with H. pylori are frequently asymptomatic, they are also associated with gastritis, peptic ulcers, and, in the most severe form, gastric cancer. Currently, gastric cancer is the fifth most common cause of cancer worldwide with a case fatality rate of 75%; these statistics make gastric cancer the third most common cause of cancerrelated death [3] . The most recent studies from the International Agency for Research on Cancer (IARC) estimates that 78% of all gastric cancers are attributable to H. pylori infection [2] . Furthermore, seroprevalence studies estimate that 90% of gastric cancer patients have encountered H. pylori [4] . Given the striking association between H. pylori and gastric cancer, decades of research have sought to determine the molecular mechanisms underlying H. pylori-associated cancer development. Indeed, numerous molecular pathways have been identified as targets of this pathogen (reviewed in [5, 6] ). Recent studies have revealed several H. pylori-targeted pathways that are also altered in various forms of cancer. Thus, a greater understanding of H. pyloriassociated cancer development may shed insight into other cancer types. Herein, we highlight recent studies that explore H. pylori's ability to induce DNA damage and aberrant methylation patterns that effect downstream host cell signaling. Additionally, we highlight recent discoveries that demonstrate how H. pylori initiates epithelial-to-mesenchymal transition (EMT) and potentiates pro-survival and proliferation signals that contribute to the cancer phenotype.
Helicobacter pylori induces DNA damage and aberrant DNA methylation Genome instability and mutation are emerging hallmarks of cancer development [7] . These genomic changes result from direct DNA damage, DNA repair failure, or via epigenetic mechanisms such as DNA methylation [7] . H. pylori targets each of these pathways: aberrant methylation [8] , decreased expression of mismatch repair genes [9] , increased expression of activation-induced cytidine deaminase [10] , and induction of double strand DNA breaks (DSBs) [ ], suggesting a role for the type IV secretion system (T4SS) in this process. This suggestion is supported by additional work that shows that the DSBs occur in a nuclear factor-kB (NF-kB) dependent manner [11 && ]. A molecular model has been proposed that suggests that binding of the T4SS pili to b 1 integrin triggers activation and translocation of NF-kB to the nucleus where it serves as a chromatin binding platform for rel-like domaincontaining protein A (RelA), the nucleotide excision repair endonucleases (NER) DNA repair protein complementing XP-G cells (XPG) and DNA repair endonuclease XPF (XPF), and recruitment factor DNA repair protein complementing XP-A cells (XPA) [11 && ]. XPA and XPF then induce DSBs that result in enhanced expression of NF-kB-dependent anti-apoptotic genes that promote cell survival [11 && ]. Taken together, these studies suggest that the DSBs induced by H. pylori are unique and perhaps directed by this pathogen.
Another mechanism by which H. pylori contributes to genomic instability is via manipulation of host gene methylation [8] . In this regard, DNA methylation is increased in the gastric antrum of H. pylori-infected patients as compared with uninfected patients [14] . DNA methylation is also increased in the 'normal tissue' surrounding the lesions [15 && ]. The role of aberrant DNA methylation in adverse disease outcome is supported by a 16-year cohort study that showed that changes in specific gene methylation can serve as predictors for gastric cancer progression [16] . Additionally, several studies have delineated the downstream consequences of altered gene methylation. For example, H. pylori has a profound effect on N-Myc downstream-regulated gene 2 (NDRG2) promoter methylation; methylation was seen in 54% of primary gastric cancer specimens [17 & ]. NDRG2 is a potential tumor suppressor that aids in dephosphorylation of the phosphatase and tensin homolog (PTEN) [18] ; PTEN is frequently found inactivated in gastric cancers because of increased levels of C-terminal phosphorylation [19] . In the active, unphosphorylated form, PTEN dephosphorylates phosphatidylinositol 3,4,5-trisphosphate (PIP3), which results in decreased phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) activity [18, 20] . Thus, as methylation increases, expression of NDRG2 decreases, PTEN C-terminal phosphorylation increases, and suppression of the PI3K/Akt pathway is relieved [17 & ,20] . It is currently thought that the upregulation of DNA methyltransferase 3b, which is correlated with H. pylori infection, is responsible for the increase in NDRG2 promoter methylation [17 & ]. DNA methylation also impacts micro-RNA (miRNA) regulation in chronic inflammatory diseases and in cancers [15 && ,21] . In H. pylori positive patients with gastric disease, aberrant methylation of the CpG island in the miR-210 promoter occurs. This methylation results in a decrease in miR-210,
KEY POINTS
Known oncogenic pathways are targeted by H. pylori through the activation of upstream signaling components or through inhibition of known tumor suppressors.
which leads to an increase in expression of miR-210 pro-proliferation targets such as stathmin 1 (STMN1) and demethyladensosine transferase 1 (DIMT1) [15 && ]. H. pylori also stimulates miRNA promoter hypermethylation via cyclooxygenase-2/prostaglandin E2 (COX-2/PGE2) activation [21] . PGE2 promotes methylation in tumor cells, and in the case of H. pylori infection, miR-149 is a target of PGE2-induced DNA methylation. miR-149 targets and suppresses interleukin-6 (IL-6) and the PGE2 receptor genes. Thus, methylation of miR-149 results in a decrease in miR-149 and an increase in IL-6. Downstream consequences of IL-6 induction include EMT, stem-like traits, and invasive properties [21] . Interestingly, IL-6 regulates the cancer cell environment by activating the COX-2/PGE2 pathway and by regulating miRNAs [21] . En masse, the data suggest that H. pylori regulates DNA damage and DNA methylation in a manner that promotes tumorigenesis via enhanced genome instability, and via the activation of cell signaling pathways that promote cellular proliferation, EMT, and stem-
Role of Helicobacter pylori in epithelial-tomesenchymal transition
One process that has taken a prominent role in cancer etiology research is EMT. EMT is critical to the developmental process; however, EMT also plays a physiopathological role in epithelial tumorigenesis [22] . During EMT, epithelial cells lose properties required to maintain a healthy cellular barrier and instead acquire mesenchymal cell-like properties: loss of cellular interactions, loss of polarization, and increased mobility [22] . Several recent studies link infection with H. pylori to EMT-like changes in gastric epithelial cells [23,24 & ,25 & ,26]. Indeed, molecular classification of gastric cancer tumors identified a cancer subtype associated with EMT [27] . This EMT subtype occurs at a younger age than the other subtypes, is associated with poor prognosis, and has a higher chance of recurrence [27] . Another clinical study found decreased expression of the epithelial marker E-cadherin and increased expression of the mesenchymal markers zinc finger protein SNAI1 (SNAIL), Twist-related protein 1 (TWIST), zinc finger protein SNAI2 (SLUG), and vimentin in tissue biopsies from H. pylori positive gastric cancer patients [24 & ]. Eradication of H. pylori results in a reversal of marker expression; E-cadherin increases whereas SNAIL, TWIST, SLUG, and vimentin decrease [24 & ]. Other studies also document EMTassociated changes in gastric epithelial cells after H. pylori infection and identify associated key players in the process [23,25 & ,26]. For example, an association between CD44 antigen (CD44) and H. pylori-induced EMT has been shown; increased CD44 is associated with a corresponding increase in mesenchymal markers [23,24 & ]. Although neither of these studies show a direct interaction between H. pylori and CD44, H. pylori may affect CD44 via suppression of miR-328, which is a known negative regulator of CD44 expression [28] . Interestingly, mir-328 expression is suppressed in response to H 2 O 2 [28] , suggesting that the gastric mucosal inflammation associated with H. pylori infection may increase host cell changes that further promote EMT.
The multipotent virulence factor, cytotoxinassociated gene A (CagA), is also directly linked to H. pylori's induction of EMT and cell proliferation via CD44 [29, 30] . Both in vivo and in vitro models demonstrate that CD44, hepatocyte growth factor receptor (c-Met), and CagA form a complex, which leads to increased cellular proliferation, an increase in mesenchymal markers [alpha-smooth muscle actin (a-SMA), SNAIL2, TWIST1, N-cadherin, and zinc finger E-box-binding homeobox 1 (ZEB1)], and disruption of membrane associated E-cadherin [29] . The increase in mesenchymal markers, CD44, and matrix metalloproteinases occurs in a CagA phosphorylation-dependent manner [30] . Similarly, transfection with CagA leads to an increase in TWIST and vimentin with a corresponding decrease in E-cadherin [23] . This later decrease in E-cadherin appears to be tied to the downregulation of programmed cell death factor 4 (PDCD4), suggesting that CagA influences EMT through multiple pathways [23] .
The factors that are commonly used as mesenchymal or epithelial markers have diverse mechanistic roles during EMT. For instance, the aforementioned decrease and disruption of E-cadherin contributes to the weakening of cell-to-cell junctions, a hallmark of EMT. Interestingly, the histone demethylase retinoblastoma binding protein 2 (RBP2) also plays a role in regulating E-cadherin; RBP2 forms a complex with phosphomothers against decapentaplegic homolog 3 (p-SMAD3) on the E-cadherin promoter to suppress E-cadherin expression [26] . These types of junctional effects are a common theme of gastric cancer and H. pylori infection. The gap junction protein, connexin-43 (Cx43), is perturbed during H. pylori infection; H. pylori induces a GATA3dependent decrease in Cx43, which leads to weakening of gastric epithelial integrity [31] . An additional study suggests that expression of Cx43 renders cells more susceptible to vacuolating cytotoxin (VacA)-induced cell death [32] . Combined, these data suggest a duel mechanism by which H. pylori generates a cell population with reduced levels of Cx43; H. pylori causes Cx43 downregulation, whereas VacA induces cell death in any cells that maintain Cx43. The end result is a defective gastric epithelial maintenance program and perhaps an increased propensity toward EMT.
Unlike the structural proteins, Cx43 and E-cadherin, SNAIL and TWIST function as transcription factors that control downstream effectors that contribute to EMT. For example, SNAIL acts as a transcriptional repressor of the gene encoding the junctional protein claudin-7 [25 & ]. Addition of H. pylori to gastric adenocarcinoma cells or a gastroid model leads to an increase in SNAIL with a corresponding decrease in claudin-7; this interaction is bcatenin dependent [25 & ]. Mechanistically, CagA binding to glycogen synthase kinase-3 (GSK-3) decreases GSK-3 activity, subsequently increasing SNAIL stability and the active, cytoplasmic form of b-catenin [33] . En masse, current data suggest that H. pylori utilizes multiple mechanisms to disrupt epithelial adhesins as a means to contribute to EMT.
Role of cell proliferation in gastric carcinogenesis
As mentioned, the interaction between CagA and b-catenin plays a role in disruption of cell-to-cell junctions, which strongly suggests that b-catenin directly or indirectly contributes to EMT. Additional evidence supports CagA-dependent, nuclear accumulation of b-catenin, which results in increased pro-proliferation gene expression; several mechanisms have been implicated in orchestrating this outcome [34] [35] [36] . Recently, the multifunctional glycol-phosphoprotein, osteopontin (OPN), has emerged as another intermediary in the CagAdependent activation of b-catenin. Intracellular OPN (iOPN) increases in a CagA and T4SS-dependent manner in response to H. pylori infection [37 & ]. Furthermore, siRNA knockdown of OPN abolishes the H. pylori-dependent nuclear accumulation of b-catenin [37 & ]. The downstream effects of the OPN increase and subsequent b-catenin nuclear localization include increases in Myc proto-oncogene protein (c-Myc) and cyclin D1 (CCDN1), both of which are known cellular proliferation contributors. These in vitro studies are supported by mouse models that show that the loss of OPN suppresses oncogenic changes, such as inflammation, epithelial proliferation, and decreased apoptosis [38, 39] .
Another major cell proliferation pathway activated during H. pylori infection is PI3K/Akt. The importance of this pathway is evidenced by the dual mechanisms of regulation by H. pylori; infection enhances cell proliferation through PI3K/Akt and suppresses proteins that inhibit PI3K/Akt activation. As mentioned above, PTEN is maintained in an inactive state following suppression of NDRG2 [17 & ,18] . As an additional control mechanism, H. pylori infection also leads to an increase in miR-221/222 expression; both of these miRNAs target PTEN as well as the tumor suppressor, reversion-inducing cysteine-rich protein with Kazal motifs (RECK) [40] . A third component altered in the PI3K/Akt pathway is 3-phosphoinositide-dependent protein kinase 1 (PDK-1). Early in infection, H. pylori dephosphorylates PDK-1, which results in dephosphorylation of Akt and induction of apoptosis; apoptosis is followed by an increase in cellular proliferation of the surviving cells [41] . Lastly, CagA induces activation of transcription factor SP1 (SP1), a downstream protein in the PI3K/ Akt pathway, via Akt [42] . SP1 serves as a transcription factor for RBP2; RBP2 binds to the CCDN1 promoter, which results in upregulation of cyclin D1 [42] . Thus, the role of RBP2 appears two-fold; RBP2 induces EMT and stemness, as well as cellular proliferation [26, 42] .
H. pylori exploits numerous targets to foster an environment geared for enhanced cellular proliferation and survival. In addition to activating pathways that promote these features, H. pylori also suppresses mechanisms meant to keep these pathways in check. For instance, H. pylori modulates several miRNAs to affect cellular proliferation. Among these, miR-203 is downregulated in H. pylori positive tissue samples [43] . This decrease results in a corresponding increase in the phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) and calcium/calmodulin-dependent serine protein kinase (CASK) targets, which in turn leads to enhanced cellular proliferation and invasion [43, 44] . Similarly, miR-101 is downregulated in H. pylori infected gastric cancer tissues [45] . Decreased levels of miR-101 result in the upregulation of suppressor of cytokine signaling 2 (SOCS2) and subsequent deregulation of the cell cycle, promoting tumorigenesis [45] . Other miRNAs downregulated during H. pylori infection, including miR-375 and miR-101b, further potentiate carcinogenic signals [46] . Thus, alteration of miRNA targets as a mechanism to promote cell survival and proliferation appears to be a broad theme employed by H. pylori.
Finally, H. pylori also has the ability to negatively influence numerous tumor suppressors. For example, gastrokine 1 has the ability to inhibit CagA-induced cell proliferation and EMT by directly binding to CagA; this interaction prevents CagA interaction with SRC homology 2 (SH2)domain-containing protein tyrosine phosphatase (SHP2) and E-cadherin [47] . However, H. pylori overcomes this effect via downregulation of gastrokine 1 in gastric cancer tissues. This is a CagA-mediated event and the resulting decreased gastrokine 1 levels result in activation of NF-kB and PI3K/Akt [47] . An additional tumor suppressor example can be found with trefoil factor 1 (TFF1), which inhibits b-catenin and NF-kB-p65 nuclear translocation via negative regulation of Akt/GSK-3b. This in turn prevents an increase in H. pylori-induced inflammation and pro-proliferation signals [48] [49] [50] . Although TFF1 can be protective, it is downregulated or lost in almost half of all adenocarcinomas [48] . Therefore, loss of TFF1 tumor suppressor activity allows for unchecked activation of b-catenin and cell proliferation through activation of c-Myc and cyclin D1 [49] . Clearly, H. pylori utilizes a multifaceted approach to induce host cell proliferation.
CONCLUSION
Although H. pylori was identified as a carcinogen over two decades ago, researchers are still elucidating novel oncogenic mechanisms used by this fascinating pathogen. Indeed, increasing evidence indicates that H. pylori can influence numerous host pathways to promote cancer development. Though all of the mechanisms are unclear, evidence suggests that as H. pylori establishes infection, the subsequent host response creates an environment conducive to tumorigenesis. Remarkably, the host cell changes undergone in response to H. pylori infection (Fig. 1) involve several hallmarks of traditional cancer progression. Included among these are DNA damage and methylation, activation of EMT pathways, activation of pro-proliferative/anti-apoptotic effectors, and suppression of tumor suppressors. H. pylori is clearly a cunning pathogen that has the ability to directly target universal cancer pathways as a means to induce gastric carcinogenesis. 
Epithelial-to-mesenchymal transition

